Insight
Two ways to minimise the impact of COVID-19 on vulnerable communities
News
Hikma expands generics portfolio with Everolimus Tablets launch
Update
Hikma update regarding COVID-19
Our 2019 preliminary results
Check out the highlights of our 2019 financial performance in this short video summary
Case study
Our support and impact for the Healthy Kitchen Project
Case study
Our support and impact; improving patient’s access to ritonavir
News
Hikma delivers strong growth in revenue and profit in 2019
CSR News
Hikma supports teachers in Jordan through new partnership with Save the Children
Find out more
Who we are. We make high quality medicines and make them accessible to the people that need them.
Our impact
The impact we have on people's lives is important, positive and far-reaching, listen to the stories of people whose lives we touch.
Find out more
Our commitment to sustainability
Find out more
We develop, manufacture and market nearly 700 quality branded and non-branded generic medicines worldwide.